AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10589753 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 135 mg/m2, i.v., over a 3-h period, escalated to 175 and 200 mg/m2; Cisplatin 80 mg/m2, i.v., day 1; Etoposide 50 mg/m2, i.v., day 1 and 100 mg/m2 p.o., days 2-3 for the first group, then 80 mg/m2, i.v., day 1 and 160 mg/m2, p.o., days 2-3 for subsequent groups
Number of subjects: 28
Study 7917734 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% prilocaine 20 ml (plain)
Number of subjects: 0
Study 7917734 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% prilocaine 20 ml (alkalinized)
Number of subjects: 0
Study 7917734 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 2973665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium 1 mg
Number of subjects: 10
Study 2973665 — intervention group
Group type: COMPARATOR
Intervention: Nebulised saline (placebo)
Number of subjects: 10
Study 2973665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium 1 mg at 6 am
Number of subjects: 10
Study 31855785 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) program, n=20
Number of subjects: 38
Study 31855785 — intervention group
Group type: COMPARATOR
Intervention: Counseling, n=18
Number of subjects: 38
Study 29866475 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly carfilzomib (70 mg/m2)
Number of subjects: 478
Study 29866475 — intervention group
Group type: COMPARATOR
Intervention: Twice weekly carfilzomib (27 mg/m2)
Number of subjects: 478
Study 29866475 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly carfilzomib
Number of subjects: 478
Study 29866475 — intervention group
Group type: COMPARATOR
Intervention: Twice weekly carfilzomib
Number of subjects: 478
Study 28188155 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation framing the patient's absolute fracture risk as the chance of having or not having an event, with benefits from osteoporosis treatment in natural frequencies or numbers needed to treat.
Number of subjects: 200
Study 24176024 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiwifruit intervention (two green kiwifruit/d plus healthy diet)
Number of subjects: 85
Study 24176024 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (healthy diet alone)
Number of subjects: 85
Study 22218119 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (PD‐Poietin)
Number of subjects: 40
Study 22218119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20380340 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-nurse-based system (group A)
Number of subjects: 102
Study 20380340 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse ambulatory system (group B)
Number of subjects: 102
Study 20380340 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 102
Study 18293123 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention (video-based)
Number of subjects: 1504
Study 18293123 — intervention group
Group type: COMPARATOR
Intervention: Control (no motivational intervention)
Number of subjects: 1504
Study 15737451 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-axis total knee arthroplasty
Number of subjects: 16
Study 15737451 — intervention group
Group type: COMPARATOR
Intervention: Multi-axis total knee arthroplasty
Number of subjects: 16
Study 12665996 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow waveform method of triggering
Number of subjects: 12
Study 12665996 — intervention group
Group type: COMPARATOR
Intervention: Traditional flow triggering (2 l/min)
Number of subjects: 12
Study 12665996 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow waveform method of cycling
Number of subjects: 12
Study 12665996 — intervention group
Group type: COMPARATOR
Intervention: Traditional flow criterion of breath termination
Number of subjects: 12
Study 10551702 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 50 mg twice daily
Number of subjects: 51
Study 10551702 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg twice daily
Number of subjects: 51
Study 8828727 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin 0.3% eye drops twice daily
Number of subjects: 45
Study 8828727 — intervention group
Group type: COMPARATOR
Intervention: Fucidic acid 1% eye drops twice daily
Number of subjects: 45
Study 1594263 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine, 0.3 mg/day
Number of subjects: 24
Study 1594263 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 24
Study 6510772 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry monopolar - Cameron Miller (M)
Number of subjects: 140
Study 6510772 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid monopolar - Storz (L)
Number of subjects: 140
Study 6510772 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar - Bicap ACMI (B)
Number of subjects: 140
Study 6510772 — intervention group
Group type: EXPERIMENTAL
Intervention: Heater probe - Seattle (H)
Number of subjects: 140
Study 31325145 — intervention group
Group type: EXPERIMENTAL
Intervention: Perifosine (PRF) 600 mg loading dose (4 divided doses on day 1) followed by 100 mg daily until disease progression or intolerable toxicity
Number of subjects: 30
Study 31325145 — intervention group
Group type: EXPERIMENTAL
Intervention: Perifosine (PRF) for patients with anaplastic astrocytoma
Number of subjects: 30
Study 29518077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 495
Study 29518077 — intervention group
Group type: EXPERIMENTAL
Intervention: Short term psychodynamic therapy (PDT)
Number of subjects: 495
Study 29518077 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (WL)
Number of subjects: 495
Study 29518077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) and Short term psychodynamic therapy (PDT)
Number of subjects: 495
Study 26539836 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidopat(®) 5% skin patch
Number of subjects: 44
Study 26539836 — intervention group
Group type: COMPARATOR
Intervention: Placebo vehicle patch
Number of subjects: 44
Study 24718702 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated ambient ultrafine particles (UCAPS) for 2 hours
Number of subjects: 34
Study 24718702 — intervention group
Group type: COMPARATOR
Intervention: Clean air for 2 hours
Number of subjects: 34
Study 23110506 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 hair grafts in the experimental square
Number of subjects: 10
Study 23110506 — intervention group
Group type: COMPARATOR
Intervention: Nongrafted control square
Number of subjects: 10
Study 20951286 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 32
Study 20951286 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Endodontic Cement (NEC)
Number of subjects: 32
Study 20951286 — intervention group
Group type: COMPARATOR
Intervention: Both MTA and NEC
Number of subjects: 32
Study 17376044 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (menatetrenone) at 45 mg per day
Number of subjects: 60
Study 17376044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin K2)
Number of subjects: 60
Study 16327351 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 63
Study 16327351 — intervention group
Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 63
Study 12046996 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-held record (PHR)
Number of subjects: 244
Study 12046996 — intervention group
Group type: COMPARATOR
Intervention: No PHR
Number of subjects: 244
Study 10209372 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/propofol auto-co-induction
Number of subjects: 54
Study 10209372 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam/propofol co-induction
Number of subjects: 54
Study 10209372 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 54
Study 7789025 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 72
Study 7789025 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 72
Study 7789025 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep venous thrombosis
Number of subjects: 72
Study 7789025 — intervention group
Group type: EXPERIMENTAL
Intervention: No deep venous thrombosis
Number of subjects: 72
Study 1954810 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg three times daily for 24 weeks
Number of subjects: 94
Study 1954810 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 94
Study 7144066 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 7144066 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31972958 — intervention group
Group type: EXPERIMENTAL
Intervention: Sil‐Oss® (experimental material)
Number of subjects: 33
Study 31972958 — intervention group
Group type: COMPARATOR
Intervention: Bio‐Oss® (control material)
Number of subjects: 33
Study 30860552 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prenatal vitamin D supplementation
Number of subjects: 0
Study 30860552 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose prenatal vitamin D supplementation
Number of subjects: 0
Study 28636505 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 200
Study 28636505 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Continuous Training (ACT)
Number of subjects: 200
Study 28636505 — intervention group
Group type: COMPARATOR
Intervention: Both AIT and ACT
Number of subjects: 200
Study 27107153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian function suppression plus standard tamoxifen
Number of subjects: 0
Study 27107153 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors as an alternative to tamoxifen with ovarian suppression
Number of subjects: 0
Study 27107153 — intervention group
Group type: COMPARATOR
Intervention: Standard tamoxifen
Number of subjects: 0
Study 24521787 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidified high-flow nasal cannula (HHHFNC)
Number of subjects: 75
Study 24521787 — intervention group
Group type: COMPARATOR
Intervention: Inhaled hypertonic saline solution (HSS)
Number of subjects: 75
Study 22284962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of periconceptional vitamins or supplements that contain folic acid
Number of subjects: 14721
Study 22284962 — intervention group
Group type: COMPARATOR
Intervention: Periconceptional vitamins or supplements that contain folic acid
Number of subjects: 14721
Study 20408346 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus sakei KCTC 10755BP
Number of subjects: 88
Study 20408346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 17588826 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20-40 mg/day
Number of subjects: 6605
Study 17588826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6605
Study 16386098 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm glucose testing
Number of subjects: 181
Study 16386098 — intervention group
Group type: COMPARATOR
Intervention: Fingertip glucose testing
Number of subjects: 181
Study 16386098 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professional conducted testing
Number of subjects: 181
Study 16386098 — intervention group
Group type: EXPERIMENTAL
Intervention: Error grid analysis
Number of subjects: 181
Study 12422101 — intervention group
Group type: EXPERIMENTAL
Intervention: External pneumatic compression (EPC) devices
Number of subjects: 44
Study 12422101 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin injections
Number of subjects: 44
Study 12422101 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EPC devices and unfractionated heparin injections
Number of subjects: 44
Study 9854453 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blockers (metoprolol or propranolol)
Number of subjects: 42
Study 9854453 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study 7832192 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF (recombinant human granulocyte‐macrophage colony‐stimulating factor)
Number of subjects: 18
Study 7832192 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF with prophylactic treatment with vitamin K
Number of subjects: 18
Study 2170883 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (alpha 2‐adrenergic antagonist)
Number of subjects: 9
Study 2170883 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (alpha 2‐adrenergic agonist)
Number of subjects: 9
Study 2170883 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control for yohimbine)
Number of subjects: 9
Study 2170883 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic comparison group
Number of subjects: 9
Study 326219 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol + Caffeine (Finimal)
Number of subjects: 216
Study 326219 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 216
Study 326219 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 216
Study 31813388 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink containing 700 mg of Ca (DAIR)
Number of subjects: 14
Study 31813388 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted diet containing 1200 mg Ca/d
Number of subjects: 14
Study 31813388 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational activities
Number of subjects: 14
Study 31813388 — intervention group
Group type: COMPARATOR
Intervention: Drink containing 0 mg of Ca (CONT)
Number of subjects: 14
Study 30537063 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cysteamine cream applied once daily for 2 and 4 months.
Number of subjects: 1
Study 30537063 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cysteamine cream applied biweekly after initial treatment.
Number of subjects: 1
Study 30537063 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cysteamine cream.
Number of subjects: 1
Study 26895847 — intervention group
Group type: EXPERIMENTAL
Intervention: SUPPORT (access to online social support tools)
Number of subjects: 63
Study 26895847 — intervention group
Group type: COMPARATOR
Intervention: NO SUPPORT (no access to online social support tools)
Number of subjects: 63
Study 26116930 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX) 70 mg
Number of subjects: 43
Study 26116930 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) 0 mg
Number of subjects: 43
Study 23261491 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) consisting of two sessions
Number of subjects: 515
Study 23261491 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 515
Study 21830062 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment
Number of subjects: 52
Study 21830062 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial CPAP treatment in OSAS group
Number of subjects: 52
Study 21830062 — intervention group
Group type: COMPARATOR
Intervention: CompSAS patients
Number of subjects: 52
Study 19240454 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents' self-review of charts
Number of subjects: 74
Study 17489880 — intervention group
Group type: EXPERIMENTAL
Intervention: NPD + L-phenylalanine (7.5 g/day)
Number of subjects: 6
Study 17489880 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (HPD, 141.3 +/‐ 3.7 g/day)
Number of subjects: 6
Study 17489880 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein diet (NPD, 73.2 +/‐ 2.6 g/day)
Number of subjects: 6
Study 15378679 — intervention group
Group type: EXPERIMENTAL
Intervention: L-theanine (200 mg)
Number of subjects: 16
Study 15378679 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg)
Number of subjects: 16
Study 15378679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11413085 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 439
Study 11413085 — intervention group
Group type: COMPARATOR
Intervention: Co-amilozide (hydrochlorothiazide 25 mg and amiloride 2.5 mg)
Number of subjects: 439
Study 9626118 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (DZ) 2 mg/kg BW.day; maximum 200 mg/day, divided into 3 doses for 8 weeks
Number of subjects: 24
Study 9626118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7701041 — intervention group
Group type: COMPARATOR
Intervention: Nicotine (0, 2, 4, 8, and 12 micrograms/kg) administered by measured‐dose nasal spray
Number of subjects: 18
Study 7701041 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (12 micrograms/kg) administered by measured‐dose nasal spray
Number of subjects: 18
Study 3665756 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-adapted pacing (Activitrax system)
Number of subjects: 23
Study 3665756 — intervention group
Group type: COMPARATOR
Intervention: Fixed-rate pacing
Number of subjects: 23
Study 30222788 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravenous (IV) and intra-articular (IA) administration of tranexamic acid (TXA)
Number of subjects: 154
Study 30222788 — intervention group
Group type: COMPARATOR
Intervention: IV only administration of tranexamic acid (TXA)
Number of subjects: 154
Study 30222788 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IV and IA administration of TXA
Number of subjects: 154
Study 30222788 — intervention group
Group type: COMPARATOR
Intervention: IV only administration of TXA
Number of subjects: 154
Study 27400145 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Spinal Epidural Anesthesia (CSEA)
Number of subjects: 22
Study 27400145 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 22
Study 27400145 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CSEA and GA
Number of subjects: 22
Study 23436914 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin for 36 months
Number of subjects: 0
Study 23436914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22512878 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal amino acid solution in the same quantity for 7 days)
Number of subjects: 45
Study 22512878 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glutamine
Number of subjects: 45
Study 20227716 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15 mg zinc + 60 mg iron + 250 microg folic acid)
Number of subjects: 421
Study 20227716 — intervention group
Group type: COMPARATOR
Intervention: Placebo (60 mg iron + 250 microg folic acid)
Number of subjects: 421
Study 20227716 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 421
Study 20227716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study 18853559 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher visualisation scores
Number of subjects: 0
Study 18853559 — intervention group
Group type: COMPARATOR
Intervention: Lower visualisation scores
Number of subjects: 0
Study 15795200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided needling followed by high-energy shock-wave therapy
Number of subjects: 40
Study 15795200 — intervention group
Group type: COMPARATOR
Intervention: Shock-wave therapy alone
Number of subjects: 40
Study 12493263 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosmidomycin for 5 days (1.2 g every 8 h)
Number of subjects: 27
Study 12493263 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosmidomycin for 4 days (1.2 g every 8 h)
Number of subjects: 27
Study 12493263 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosmidomycin for 3 days (1.2 g every 8 h)
Number of subjects: 27
Study 10909495 — intervention group
Group type: EXPERIMENTAL
Intervention: Program I (individual, motivating instructions of oral cavity hygiene, 10 meetings)
Number of subjects: 223
Study 10909495 — intervention group
Group type: EXPERIMENTAL
Intervention: Program II (expanded educational activity among children and parents)
Number of subjects: 223
Study 10909495 — intervention group
Group type: EXPERIMENTAL
Intervention: Program III (expanded educational activity, professional mechanical tooth-cleaning, fissure sealants, intensive dental care, proximal surface cleaning)
Number of subjects: 223
Study 10909495 — intervention group
Group type: COMPARATOR
Intervention: Control group K (no specific intervention)
Number of subjects: 223
Study 7864422 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane at 0.3% end-tidal level (Group I)
Number of subjects: 30
Study 7864422 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane at 0.6% end-tidal level (Group II)
Number of subjects: 30
Study 7864422 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane at 1.2% end-tidal level (Group III)
Number of subjects: 30
Study 2387655 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201-995 (10-hour i.v. infusion at a rate of 8 g/min)
Number of subjects: 5
Study 2387655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 7016245 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded pressure stockings
Number of subjects: 76
Study 7016245 — intervention group
Group type: COMPARATOR
Intervention: Control (no stockings)
Number of subjects: 76
Study 7016245 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion during operation
Number of subjects: 76
Study 30900268 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-enriched formula (EE-formula) (1 kcal/mL)
Number of subjects: 59
Study 30900268 — intervention group
Group type: COMPARATOR
Intervention: Normocaloric formula (0.67 kcal/mL)
Number of subjects: 59
Study 31084562 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) applied three times a week for 4 weeks
Number of subjects: 43
Study 31084562 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave therapy (ESWT) applied once a week for 4 weeks
Number of subjects: 43
Study 27813150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariex® spray combined with non-surgical periodontal therapy
Number of subjects: 24
Study 27813150 — intervention group
Group type: COMPARATOR
Intervention: Cariex® spray alone
Number of subjects: 24
Study 27813150 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical periodontal therapy alone
Number of subjects: 24